
The world's largest iceberg is on the move again
The iceberg in question is A-23A, sometimes called A23a. It is the world's oldest and largest — about the size of Rhode Island — and weighs nearly 1 trillion tonnes. As it moves along, the biggest concern, scientists say, is whether the iceberg or its bits could block access to parts of the island for wildlife or ships. Previous iceberg collisions have affected food foraging on the island.
The ice slab is meandering and moving parallel to South Georgia Island, oceanographer Andrew Meijers said. Currents are expected to loop A-23A back to South Georgia's continental shelf in about two weeks.
'If it does ground on the continental shelf ... this could pose a significant problem for seals and [penguins] presently feeding their chicks and pups,' said Meijers, a researcher at the British Antarctic Survey.
The iceberg is drifting in a current at about 1 kilometer per hour (about 0.62 miles per hour) toward South Georgia. Although its arrival could occur in weeks, Meijers said, 'it is hard to be precise as wind and wave action can also be important and eddies in the current are very hard to predict.'
'The iceberg might take a turn around South Georgia like many before it' or smaller pieces broken off from the iceberg could run aground, said Jan Lieser, marine glaciologist at the Australian Antarctic Program Partnership.
South Georgia Island is a difficult place for humans to live, but it is a haven for wildlife. Its productive waters support abundant populations of krill, which serve as food for many marine predators like fur seals. In fact, more than 3.5 million fur seals live on the island, which is about 95 to 98 percent of the world's population of the animal. Deep bays also provide homes for millions of penguins and seabirds — including the wandering albatross, which is threatened.
In 2004, an iceberg grounded on the north side of South Georgia and was associated with more seal pup and penguin chick mortalities, Meijers said. When the iceberg grounded, it likely made foraging more difficult.
'The adults must swim further to go around the berg and thus expend more energy and bring back less,' Meijers said.
In 2021, another iceberg about the size of Delaware appeared on a collision course with South Georgia but then fractured into smaller pieces around the island.
The British Antarctic Survey expects A-23A to encounter warmer water and break up into smaller icebergs and, eventually, melt.
If iceberg A-23A breaks up before hitting the island, the impact will be lessened because smaller chunks are easier for wildlife to go around. Fishing vessels, though, might have a harder time navigating around thousands of smaller chunks, Meijers said.
One chunk — measuring 80 square kilometers — broke off A-23A in late January. Leiser said the piece is large enough to be given identifying numbers and letters by the U.S. National Ice Center.
Now, A-23A is sitting in 'a bit of storm' with sustained winds around 70 kilometers per hour (about 44 miles per hour) and waves as high as 6 meters (about 6½ feet), Meijers said. This storm may speed up the break up of the iceberg.
The iceberg's path isn't unusual, nor is it the first to venture to South Georgia Island.
Iceberg A-23A broke off the Filchner-Ronne Ice Shelf to the northeast of the West Antarctic Ice Sheet in 1986. It then spent decades stuck to the seafloor. In the early 2020s, the iceberg began to loosen and by March 2023, it floated freely. One year later, as it drifted north, it became trapped in a gyre — and it would remain in the rotating system of ocean currents until it escaped several months later.
The mass mostly took the same path as other large icebergs exiting the Weddell Sea, heading down 'iceberg alley,' Lieser said.
Iceberg alley starts on the northeastern side of the Antarctic Peninsula and generally heads northeast past the South Orkney Island and South Georgia Island into the South Atlantic Ocean.
'The unusual part of the iceberg's journey was the long time it was trapped in this oceanic gyre,' said Lieser, who is also a research associate at the Institute for Marine and Antarctic Studies at the University of Tasmania.
This ocean gyre is known as a Taylor column, where rotating water above a seamount trapped the iceberg from drifting north. Imagine placing a stick in a swirling bucket of water; the water flowing around the stick forms a Taylor column.
Lieser doesn't know why the iceberg escaped the vortex, but hypothesizes that a 'random perturbation in the system' might have affected its 'usual spin,' allowing the iceberg to find an exit path.
Only time will tell if iceberg A-23A will make another rare maneuver onto South Georgia and disrupt the animals.
'The exact degree of impact will depend on how closely the berg grounds, and whether or not this sits on the optimal path to [or] from the breeding beaches and feeding ground,' Meijers said. 'This is pretty much impossible to predict.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Will medtech M&A pick back up in the second half?
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The medical device industry kicked off 2025 similarly to most years: Top companies were spending money. Stryker, Zimmer Biomet and Thermo Fisher Scientific all announced deals worth more than $1 billion, and Boston Scientific, after a rush of M&A last year, announced a pair of acquisitions that could collectively eclipse that mark. However, activity has since cooled, with few transactions taking place outside of the first two months of the year. 'The number of medtech M&A deals for the first half of the year, technically, is on pace to match last year's … but it has been really front-loaded,' said Aaron DeGagne, a senior healthcare analyst with PitchBook. Stryker's nearly $5 billion pickup of Inari Medical — the year's highest price tag so far — was announced Jan. 6. Rival Zimmer Biomet revealed it would buy Paragon 28 for $1.1 billion a few weeks later. And Thermo Fisher Scientific agreed to buy Solventum's purification and filtration business for $4.1 billion in February. Meanwhile, Boston Scientific's deal worth up to $664 million for the remaining stake of Bolt Medical and its purchase of Sonvie, worth up to $540 million, were announced in early January and March, respectively. Since then, the M&A environment has been quiet, with few acquisitions, let alone a billion-dollar or multi-billion-dollar purchase. Analysts said in interviews that the slowdown in dealmaking is due to similar factors as the slowdown in initial public offerings after a handful of companies went public in the span of a few months: economic uncertainty and an up-and-down market, largely due to the Trump administration's tariff policies. Companies tightened their pocketbooks as the market dropped and questions swirled about the impact of the Trump administration's trade strategy. 'Part of the reason for [the slowdown] is when you have these transactions, especially as they get into the hundreds of millions — and into the billions — these are deals that are being worked on for not just weeks, but usually worked on for months, or even years,' DeGagne said. 'When we get some of these deals announced in January, February, March — I think the ball got rolling on these either early this year or late last year, when I think the market was in a pretty good place.' Shagun Singh, an analyst with RBC Capital Markets, said companies wanted to see how the tariffs would affect their businesses shortly after the policies were announced, and that they wanted to 'see what the headwinds are, what they need to do, how they need to manage it.' The Trump administration's tariff policies have affected medtech companies in different ways — some saw little impact, while companies like Johnson & Johnson, Abbott and Boston Scientific projected charges worth hundreds of millions of dollars. Questions still exist about how businesses will move forward as trade tensions with China and other countries have, for now, eased. John Babitt, a partner with EY, added that deals announced in the first quarter, like Stryker's and Zimmer's, would have been 'a lot more difficult to get done post-tariff announcement.' With uncertainty looming around tariffs, specifically, buyers may value companies less if they are exposed to the trade policies, PitchBook's DeGagne said. He added that an uncertain and complex market in general forces companies to take a closer look at their spending, which can influence whether acquisitions will be made. 'Generally speaking, market uncertainty creates difficult business environments, and so a lot of these big public companies are scrutinizing their costs,' DeGagne said. 'They don't know if their customers are going to continue buying, and so … they will be less likely to, probably, go ahead with a high price transaction in that environment.' Dealmaking is expected to resume in the second half, the analysts said, as the economic environment stabilizes a bit more. After weathering a turbulent past few months, Singh said companies are 'back in a mood where they are thinking about their businesses and thinking about long-term strategies.' And while there is still uncertainty about the future of tariff policies and other macroeconomic factors, companies may still be willing to pull the trigger on M&A when the opportunity arises. 'I don't think there is expectation that the worst is behind us. I think there is uncertainty right now. I don't know if there's a good time,' Singh said. 'I think companies are going to be opportunistic.' EY's Babitt said that people are 'cautiously optimistic' that medtech firms will spend more later this year compared to the first half, adding that his company is seeing that sentiment in 'the activity in our business as well.' One strategy companies are using is a dual-process approach, where they are simultaneously pursuing a sale and an IPO, according to Babitt. 'It drives a little competitive tension to draw investors in,' he added. Illumina has already broken through the slump, announcing in June that it would buy SomaLogic for up to $425 million. Executives from some of the industry's biggest spenders — Boston Scientific and Stryker — have also signaled that they're open to continuing their M&A runs. 'We're fine and good to go,' Boston Scientific CEO Mike Mahoney said at a May investor event when questioned if the company would slow down on M&A. He explained that the company is focused on 'putting ourselves in faster-growth markets and expanding our category leadership so we can partner with customers better … We think that playbook's smart. We're effective at it. We are very good at doing integrations.' Mahoney added that the company is in 'enough businesses with so much unmet need that there's plenty of things to look at.' Meanwhile, CFO Preston Wells said in May that Stryker, which closed seven deals last year, is in a 'very good position from a liquidity standpoint, and [we] certainly still have the ability to go out and tap the debt markets if necessary and the right deal comes through.' Boston Scientific and Stryker have been some of the most active spenders in the medtech space, pursuing tuck-in deals that allow them to lead in specific business categories. Other medtech companies are expected to pursue similar strategies as the industry continues to move away from simply growing in sheer size. When discussing potential acquisitions, EY's Babitt called out surgical robotics, pulsed field ablation, structural heart and diabetes as areas that 'have a lot of growth and therefore interest.' He did not name specific companies in terms of targets or buyers. RBC's Singh believes the M&A environment is wide open. 'It's going to be all over the place,' Singh said. 'I really think that it's going to be diverse.' While the number of total transactions may not reach the heights of prior years, largely due to the months-long slowdown, the industry could see M&A pick up in the near future. 'M&A is just going to continue. I think it's the lifeblood of medtech,' Singh said. 'You're not going to pass up an opportunity because of tariffs if you can get into a multi-billion dollar market and you have an asset right in front of you.' Recommended Reading The medtech IPO window is finally open. Or is it?


Business Wire
2 days ago
- Business Wire
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani, Ph.D., Chair of Quince's Scientific Advisory Board, said, 'Quince is excited to welcome leading immunologist and researcher Dr. Abolhassani as a new member of our SAB. Given his notable work in immunodeficiency disorders, as well as the rare pediatric neurodegenerative disease Ataxia-Telangiectasia, we expect to benefit from his unique insight and expertise as the SAB continues to support Quince as the company advances its potentially breakthrough ability to deliver corticosteroid treatment without toxicities with its lead asset eDSP.' Dr. Hassan Abolhassani said, 'It is an honor to join Quince's SAB at this exciting time as the company prepares to report topline results in the first quarter of 2026 evaluating the company's lead asset, eDSP, for the treatment of patients with A-T. I look forward to collaborating with the distinguished members of Quince's management team, Board of Directors, and Scientific Advisory Board to support the advancement of eDSP for the treatment of not only A-T but for additional potential immunological and autoimmune focused rare disease indications.' Hassan Abolhassani, M.D., Ph.D., currently serves as Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden where he also is the team leader of pediatrics primary immunodeficiency (PID) and inborn errors of immunity (IEI) research in the lab of Professor Qiang Pan Hammarström, M.D., Ph.D. Dr. Abolhassani's translational clinical research aims to investigate the pathogenesis of primary antibody deficiency and the immune pathways involved that may help physicians and immunologists to understand genes with currently unknown functions and to aid in deciding therapeutic approaches for patients. Additionally, his work includes multidisciplinary and translational approaches for diagnosis and treatment of Ataxia-Telangiectasia. Dr. Abolhassani is recognized in the top 1% of highly cited scientific researchers in the field of immunology (Essential Science Indicators) and the world's top 2% widely cited scientists (Scopus/Elsevier). He has received several awards, including the Isil Berat Barlan Award in primary immunodeficiency diseases, the Anna-Greta Crafoords Prize for rheumatologic research, the USERN Prize in medical sciences, the Jonas Söderquist Award in virology and immunology, and the Razi Festival Award in medical sciences, among others. Dr. Abolhassani is the president of the Middle East and North Africa Registry on Inborn Errors of Immunity, one of the largest PID/IEI cohorts worldwide, is a steering member of the J Project, a professional network of experts on PID/IEI, and a distinguished clinical immunologist collaborator of the Global Burden of Disease study led by the Institute for Health Metrics and Evaluation at the University of Washington, Seattle. Dr. Abolhassani received a M.D. from Tehran University of Medical Sciences where he also completed an internship for immune disorders at the Research Center for Immunodeficiencies. Additionally, he received a Ph.D. in clinical immunology and immunogenetics of chronic infectious and inflammatory disease from the Karolinska Institutet where he also completed his postdoctoral fellowship in single-cell multi-omics. Dr. Abolhassani holds a Master of Public Health and a Master of Philosophy from Tehran University of Medical Sciences and received a Doctor of Philosophy from the Karolinska Institutet. Quince's SAB provides expert insight and advice to support the advancement of its lead asset eDSP for the treatment of A-T for which a pivotal Phase 3 clinical trial is currently underway. The SAB also serves as a valuable resource as the company strategically expands its development pipeline by pursuing other potential rare disease indications beyond A-T and Duchenne muscular dystrophy (DMD) for eDSP where chronic corticosteroid treatment is – or has the potential to become – a standard of care, if there were not corticosteroid-related safety concerns. The prioritized list of other potential rare disease targets under consideration includes: 1) autoimmune hepatitis, 2) pulmonary sarcoidosis, 3) dermatomyositis, 4) pemphigus vulgaris, 5) Hashimoto's encephalopathy, 6) Becker muscular dystrophy, 7) pediatric lupus, 8) juvenile idiopathic arthritis, 9) myasthenia gravis, 10) limb-girdle muscular dystrophy, and 11) chronic inflammatory demyelinating polyradiculoneuropathy. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as 'believe,' 'may,' 'should,' 'expect,' 'anticipate,' 'plan,' 'believe,' 'estimated,' 'potential,' 'intend,' 'will,' 'can,' 'seek,' or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled 'Risk Factors' in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 24, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
Yahoo
6 days ago
- Yahoo
Royal Navy ship given freedom of inland city
A Royal Navy ship has been given a Freedom of the City honour by a city that is about 50 miles from the nearest bit of coast. HMS Protector was given the award by Cambridge City Council at the city's military fair last month. The vessel, an ice patrol ship usually based in Antarctica, has been recognised for its ongoing contributions to researching climate change and works with two research organisations from Cambridge, the council said. Dinah Pounds, Labour councillor who presented the award, said: "We are very grateful for their work and contributions to tackling climate change." Working in the Antarctic, the ship has supported scientific research, wildlife mapping, researching changing climate and the continent's shifting waters. This work is carried out by the Scott Polar Research Institute and the British Antarctic Survey – both based in Cambridge. Pound added: "We declared a climate change emergency in 2019, and lot of work has gone into making Cambridge more climate resilient. "This is a wonderful way to show support for the men and women who make up the Armed Forces community." The Freedom of the City parade at Parker's Piece included people from HMS Protector, armed forces veterans and cadets. Capt Tom Weaver said he looked "forward to strengthening the relationship" between the city and the ship while they continued their "research into the impacts of climate change and human activity" on the south pole continent. Councillors last awarded Freedom of the City to the Hungarian city of Szeged in 2011. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X. Councillors back ship getting Freedom of the City Ship could be awarded Freedom of the City Navy icebreaker completes mission to Antarctic Cambridge City Council